FRIDAY, Sept. 22, 2023 (HealthDay News) – New research suggests some newer diabetes treatments may not be as beneficial for Black patients, after earlier drug trials included small numbers of non-white people. Whether the medications — called sodium-glucose co-transporter 2 inhibitors (SGLT2-Is) and glucogen-like peptide 1 receptor agonists (GLP1-Ras) —Continue Reading

THURSDAY, Sept. 21, 2023 (HealthDay News) — Helping undocumented immigrants in the United States connect with primary care doctors could be a money-saver, substantially reducing emergency department use and lowering health costs, a new study finds. The findings are from a New York City program that helped arrange medical appointmentsContinue Reading

WEDNESDAY, Sept. 20, 2023 (HealthDay News) — In a surprising move, the U.S. Food and Drug Administration (FDA) has opted not to approve a needle-free alternative to the EpiPen for emergency treatment of severe allergic reactions. Approval of the Neffy nasal spray was widely anticipated. An FDA advisory panel votedContinue Reading